WayPoint Biomedical Holdings Inc
WayPoint Biomedical Holdings, Inc., through its wholly owned subsidiary, WayPoint Biomedical, Inc., engages in the development and marketing of diagnostic tests and devices for screening and monitoring human health, fitness, and environment. It offers a drink spiking test, the Drink Detective, used to detect date rape drugs, including Ketamine, GHB, and Benzodiazapines; and Health Essist tests fo… Read more
WayPoint Biomedical Holdings Inc (WYPH) - Net Assets
Latest net assets as of June 2006: $-335.91K USD
Based on the latest financial reports, WayPoint Biomedical Holdings Inc (WYPH) has net assets worth $-335.91K USD as of June 2006.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($499.87K) and total liabilities ($835.79K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-335.91K |
| % of Total Assets | -67.2% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
WayPoint Biomedical Holdings Inc - Net Assets Trend (2004–2005)
This chart illustrates how WayPoint Biomedical Holdings Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for WayPoint Biomedical Holdings Inc (2004–2005)
The table below shows the annual net assets of WayPoint Biomedical Holdings Inc from 2004 to 2005.
| Year | Net Assets | Change |
|---|---|---|
| 2005-12-31 | $-417.88K | -179.35% |
| 2004-12-31 | $-149.59K | -- |
Equity Component Analysis
This analysis shows how different components contribute to WayPoint Biomedical Holdings Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 54427700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2005)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $275.98K | % |
| Total Equity | $-417.88K | 100.00% |
WayPoint Biomedical Holdings Inc Competitors by Market Cap
The table below lists competitors of WayPoint Biomedical Holdings Inc ranked by their market capitalization.
Equity Growth Attribution
This analysis shows how different factors contributed to changes in WayPoint Biomedical Holdings Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2004 to 2005, total equity changed from -149,589 to -417,883, a change of -268,294.
- Net loss of 544,277 reduced equity.
- Other factors increased equity by 275,983.
Equity Change Factors (2004 to 2005)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-544.28K | -130.25% |
| Other Changes | $275.98K | +66.04% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares WayPoint Biomedical Holdings Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently WayPoint Biomedical Holdings Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1829.87%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | $-134.63K |
| 2005 | 0.00% | -1829.87% | 0.45x | 0.00x | $-502.49K |
Industry Comparison
This section compares WayPoint Biomedical Holdings Inc's net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $36,677,338
- Average return on equity (ROE) among peers: -64.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| WayPoint Biomedical Holdings Inc (WYPH) | $-335.91K | 0.00% | N/A | $0.98 |
| Artius II Acquisition Inc. Class A Ordinary Shares (AACB) | $-60.27K | 0.00% | 0.00x | $198.37 Million |
| Artius II Acquisition Inc. Units (AACBU) | $-60.27K | 0.00% | 0.00x | $205.28 Million |
| Ares Acquisition Corporation II (AACT-UN) | $931.34 Million | 0.00% | 0.08x | $399.77 Million |
| AA Mission Acquisition Corp. (AAM-UN) | $-559.90 Million | 0.00% | 0.00x | $349.76 Million |
| Global Acquisitions Corporation (AASP) | $3.80 Million | -5.26% | 0.34x | $15.42 Million |
| ABV Consulting Inc (ABVN) | $8.75K | -623.31% | 2.50x | $461.96K |
| Atlantic Coastal Acquisition Corp II (ACAB) | $-8.52 Million | 0.00% | 0.00x | $2.44 Million |
| Annabidiol Corp (ACBD) | $-501.57K | 0.00% | 0.00x | $13.62K |
| ACRO Biomedical Co Ltd (ACBM) | $685.87K | -17.12% | 0.46x | $30.04K |
| Huaizhong Health Group Inc (ADAD) | $-19.47K | 0.00% | 0.00x | $3.15K |